Abstract
Abstract
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. However, its unique pharmacological portfolio speaks to the idea of a pluripotent agent with a broad therapeutic potential. Here, authors briefly discuss these off-label clinical indications synthesizing the extant evidence.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Clinical Neurology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Symptoms and conventional treatments of Alzheimer's disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024
2. Understanding the role of alkaloids in therapeutic targeting of UBE3A in Alzheimer's Disease;2023 3rd International Conference on Innovative Sustainable Computational Technologies (CISCT);2023-09-08